Search results for " eosinophil"

showing 10 items of 57 documents

Treating severe asthma:Targeting the IL‐5 pathway

2021

Abstract Severe asthma is a heterogeneous disease with different phenotypes based on clinical, functional or inflammatory parameters. In particular, the eosinophilic phenotype is associated with type 2 inflammation and increased levels of interleukin (IL)‐4, IL‐5 and IL‐13). Monoclonal antibodies that target the eosinophilic inflammatory pathways (IL‐5R and IL‐5), namely mepolizumab, reslizumab, and benralizumab, are effective and safe for severe eosinophilic asthma. Eosinophils threshold represents the most indicative biomarker for response to treatment with all three monoclonal antibodies. Improvement in asthma symptoms scores, lung function, the number of exacerbations, history of late‐o…

0301 basic medicineImmunologyReview ArticleDisease03 medical and health scienceschemistry.chemical_compound0302 clinical medicineReslizumabEosinophilicHumansImmunology and AllergyMedicineInvited ReviewsAnti-Asthmatic AgentsInterleukin 5Asthmabusiness.industryAnti-Asthmatic Agents Asthma Eosinophils Interleukin-5medicine.diseaseBenralizumabAsthmaEosinophils030104 developmental biology030228 respiratory systemchemistryImmunologyBiomarker (medicine)Interleukin-5businessMepolizumabmedicine.drug
researchProduct

Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma.

2020

Background: Inflammation is a long-established hallmark of liver fibrosis and carcinogenesis. Eosinophils are emerging as crucial components of the inflammatory process influencing cancer development. The role of blood eosinophils in patients with hepatocellular carcinoma receiving systemic treatment is an unexplored field. Objective: The objective of this study was to analyse the prognostic role of the baseline eosinophil count in patients with sorafenib-treated hepatocellular carcinoma. Patients and Methods: A training cohort of 92 patients with advanced- or intermediate-stage sorafenib-treated hepatocellular carcinoma and two validation cohorts of 65 and 180 patients were analysed. Overa…

0301 basic medicineOncologySorafenibAdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisCarcinoma HepatocellularInflammationAdult; Aged; Aged 80 and over; Carcinoma Hepatocellular; Eosinophils; Female; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Sorafenib; Survival Analysis; Young AdultCapecitabine03 medical and health scienceschemistry.chemical_compoundYoung Adult0302 clinical medicineInternal medicineRegorafenib80 and overmedicineHumansPharmacology (medical)AgedAged 80 and overSettore MED/12 - Gastroenterologiabusiness.industryCarcinomaLiver NeoplasmsHepatocellularhepatocellular carcinomaEosinophilMiddle AgedSorafenibmedicine.diseasePrognosisSurvival AnalysisConfidence intervalEosinophils030104 developmental biologymedicine.anatomical_structureOncologychemistry030220 oncology & carcinogenesisHepatocellular carcinomaFemalemedicine.symptombusinessmedicine.drugTargeted oncology
researchProduct

Epithelioid Hemangioma (Angiolymphoid Hyperplasia With Eosinophilia) of the Heart With Peripheral Eosinophilia and Nephrotic Syndrome

2015

Epithelioid hemangioma (EH) is a rare benign vascular lesion, characterized by endothelial cells with epithelioid/histiocytoid appearance. Heart involvement is extremely rare. We present an unusual case of cardiac EH in a young woman with supraventricular arrhythmia, nephrotic syndrome (membranous glomerulopathy), and peripheral eosinophilia after a pregnancy and normal partum resembling Kimura disease. Echocardiogram showed a large tumor mass in the right cardiac ventricle. The cardiac tumor was removed and the histopathology revealed an endothelial proliferation associated with abundant eosinophils. The neoplastic endothelial cells were eosinophilic and polygonal with epithelioid/histioc…

AdultCD31medicine.medical_specialtyPathologyNephrotic SyndromeHeart Diseases030204 cardiovascular system & hematologyPathology and Forensic MedicineHemangioma03 medical and health sciences0302 clinical medicineEosinophilicmedicineHumansEosinophiliaAngiolymphoid hyperplasia with eosinophiliaEpithelioid Hemangiomabusiness.industryEndothelial CellsAngiolymphoid Hyperplasia with Eosinophiliamedicine.disease030220 oncology & carcinogenesisFemaleSurgeryKimura DiseaseHistopathologyAnatomymedicine.symptomHemangiomabusinessInternational Journal of Surgical Pathology
researchProduct

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.

2020

Background: Current availability of several biologic treatments for severe asthma makes it possible to choose the most appropriate for each patient. Sometimes a good percentage of patients with severe asthma may be eligible for biologics that target either the allergic phenotype or the eosinophilic one, but not all respond to that selected as first choice. The aim of our real-life study was to assess whether, for patients with severe eosinophilic allergic asthma, not previously controlled by the anti-IgE omalizumab, the shift to another biologic targeting interleukin-5, such as mepolizumab, may represent a good therapeutic choice. Methods: A total of 41 consecutive patients with severe, per…

AdultMale0301 basic medicinePulmonary and Respiratory Medicinesevere asthmamedicine.medical_specialtyTime FactorsSevere asthmamepolizumab omalizumab severe asthma switchingOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioAntibodies Monoclonal HumanizedSeverity of Illness Index03 medical and health sciences0302 clinical medicinereal lifeAnti-Allergic AgentsHumansMedicineswitching.Pharmacology (medical)Anti-Asthmatic AgentsPulmonary EosinophiliaIntensive care medicineLungOriginal ResearchAgedRetrospective Studieslcsh:RC705-779switchingDrug Substitutionbusiness.industrymepolizumablcsh:Diseases of the respiratory systemMiddle AgedAsthmaTreatment Outcome030104 developmental biologyItaly030228 respiratory systemomalizumabFemalebusinessMepolizumabmedicine.drug
researchProduct

Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy.

2009

Background: To date, no predictive tests for the clinical response to allergen-specific immunotherapy (ASI) are available. Therefore an in vivo or in vitro test would be of great value. Objective: We sought to evaluate pretreatment parameters used in diagnosing allergic rhinitis and determining serum specific IgE (s-IgE) levels, serum total IgE (t-IgE) levels, and blood eosinophil counts and to identify whether can be used to predict clinical improvement in monosensitized patients with allergic rhinitis with or without asthma treated with immunotherapy. Methods:We analyzed 279 patients who had undergone 4 years of ASI administered either by means of the subcutaneous immunotherapy (76 patien…

AdultMaleAllergySettore MED/09 - Medicina InternaRhinitis Allergic PerennialAdolescentmedicine.medical_treatmentImmunologyspecific IgEImmunoglobulin Eblood eosinophil countsYoung AdultBlood serummedicineImmunology and AllergyHumansreceiver operating characteristic curveAsthmaDesensitization (medicine)Retrospective StudiesSkin Testsserum s-IgE/total IgE ratio; allergen-specific immunotherapyHouse dust miteserum s-IgE/total IgE ratiobiologyserum-specific IgE/serum total IgE ratiobusiness.industryAllergen-specific immunotherapy; blood eosinophil counts; receiver operating characteristic curve; serum-specific IgE/serum total IgE ratio; specific IgE; total IgEArea under the curveImmunotherapyAllergensImmunoglobulin EMiddle Agedmedicine.diseasebiology.organism_classificationPrognosisAllergen-specific immunotherapyBlood Cell Counttotal IgEEosinophilsTreatment OutcomeDesensitization ImmunologicSpirometryImmunologybiology.proteinFemalebusiness
researchProduct

Uncommon clinical presentation of Kimura’s disease as bilateral retroauricular masses in a young Malian male: successful surgical approach.

2016

We present a case of a 27 year-old Malian male referred to our hospital for two large, painless retroauricolar masses that had appeared two years earlier. Bilateral cervical painless lymphadenopathy was present at physical examination, without any other systemic symptoms. His history was relevant for bilateral Kimura’s disease lesions resected 5 years earlier in the same locations. Lymphocytosis and a mild hypereosinophilia were found in routine blood tests, together with increased total IgE levels. After surgery, histology showed lymphoid infiltrates with reactive prominent germinal centres containing eosinophils, suggesting relapse of Kimura’s disease, in the context of nonencapsulated fi…

AdultMaleKimura diseaseCancer ResearchPhysiologyEndocrinology Diabetes and MetabolismImmunologyAngiolymphoid Hyperplasia with EosinophiliaNon-AsianFibrosisKeloid Kimura disease neck retroauricolar non-AsianTreatment OutcomeEndocrinologyOncologyRecurrenceKeloidPhysiology (medical)retroauricolarHumansImmunology and AllergyRetroauricularNeck
researchProduct

Differences and Similarities between Allergic and Nonallergic Rhinitis in a Large Sample of Adult Patients with Rhinitis Symptoms

2010

<i>Background:</i> Allergic rhinitis (AR) and nonallergic rhinitis (NAR) may present with different clinical and laboratory characteristics. <i>Methods:</i> A total of 1,511 consecutive patients, aged 18–81 years, diagnosed with rhinitis, 56% females and 44% males, underwent complete allergic evaluation including skin prick test, blood eosinophil counts, nasal eosinophil counts, peak nasal inspiratory flow (PNIF) measurement and evaluation of nasal symptoms using a visual analog scale (VAS). <i>Results:</i> A total of 1,107 patients (73%)had AR, whereas 404 (27%) had NAR. Patients with NAR were older and predominantly female. A higher nasal eosinophils co…

AdultMaleNasal eosinophilAgingAllergyRhinitis Allergic PerennialSkin prick testPeak nasal inspiratory flowAdolescentNon allergic rhinitisVisual analogue scaleNon-allergic rhinitisImmunologyHistamine AntagonistsReceiver operating characteristicSettore MED/42 - Igiene Generale E ApplicataSeverity of Illness IndexAllergic rhinitisYoung AdultSex FactorsNonallergic rhinitisBlood eosinophilAllergic rhinitis; Non allergic rhinitis; Skin prick test; Peak nasal inspiratory flow; Blood eosinophil; Nasal eosinophil; Visual analog scale; Receiver operating characteristicHumansImmunology and AllergyMedicineAllergic rhinitis Non allergic rhinitis Skin prick test Peak nasal inspiratory flow Blood eosinophil Nasal eosinophil Visual analog scale Receiver operating characteristicVisual analog scaleYoung adultAgedRhinitisSkin TestsAged 80 and overAdult patientsbusiness.industryHeadacheGeneral MedicineMiddle AgedEosinophilConjunctivitismedicine.diseaseLarge sampleEosinophilsmedicine.anatomical_structureSettore MED/31 - OtorinolaringoiatriaImmunologyFemaleNasal Obstructionbusiness
researchProduct

Reslizumab as add-on therapy in patients with refractory asthma

2020

### Key messages #### What is the key question? #### What is the bottom line? #### Why read on? Asthma is a common disease, affecting an estimated 334 million people worldwide, with considerable impact on quality of life and high associated costs.1–3 Asthma severity is assessed retrospectively from the level of treatment required to control symptoms and exacerbations. Approximately 5%–10% of patients with asthma are believed to suffer from severe disease.4 Patients with severe asthma typically require ongoing maintenance therapy with high-dose inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA).2 Furthermore, systemic corticosteroids (SCS) are often required for potentially life-th…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classCost-Benefit Analysislcsh:MedicineInflammationAntibodies Monoclonal HumanizedYoung Adult03 medical and health sciences0302 clinical medicineReslizumabQuality of lifeMaintenance therapyAdrenal Cortex HormonesInternal medicinemedicineHumans1506Anti-Asthmatic Agents030212 general & internal medicineChildAdrenergic beta-2 Receptor AgonistsPulmonary EosinophiliaAgedAsthmalcsh:RC705-779business.industrylcsh:Rlcsh:Diseases of the respiratory systemMiddle AgedEosinophilmedicine.diseaseAsthmarespiratory tract diseasesTreatment Outcomemedicine.anatomical_structure030228 respiratory systempulmonary eosinophiliaRegression AnalysisCorticosteroidFemalemedicine.symptombusinessmedicine.drugBMJ Open Respiratory Research
researchProduct

Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.

2019

Background An estimated 7% of patients with asthma have chronic rhinosinusitis with nasal polyps (CRSwNP), and more than 80% have at least some radiographic evidence of sinonasal inflammation. Aspirin sensitivity is strongly associated with elevated blood eosinophil levels and increased asthma severity. Intravenous (IV) reslizumab has been shown to improve asthma control in patients with nasal polyps. Objective These post hoc analyses of pooled data from 2 BREATH phase 3 clinical trials, studies 1 and 2 (NCT01287039 and NCT01285323), examined asthma-related outcomes in patients with comorbid, self-reported CRSwNP with and without aspirin sensitivity. Methods Patients aged 12-75 years with e…

AdultMalemedicine.medical_specialtyAdolescentComorbidityPlaceboAntibodies Monoclonal Humanized03 medical and health sciencesYoung Adult0302 clinical medicineNasal PolypsReslizumabMaintenance therapyInternal medicinemedicineImmunology and AllergyHumansNasal polyps030212 general & internal medicineAnti-Asthmatic AgentsPulmonary EosinophiliaSinusitisChildAsthmaAgedRhinitisAspirinbusiness.industryMinimal clinically important differenceAnti-Inflammatory Agents Non-SteroidalEosinophilMiddle Agedmedicine.diseaseAsthmarespiratory tract diseasesEosinophilsmedicine.anatomical_structureTreatment Outcome030228 respiratory systemAsthma Control QuestionnaireChronic DiseaseFemaleSelf Reportbusinessmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

2012

BACKGROUND: Some patients with severe asthma have recurrent asthma exacerbations associated with eosinophilic airway inflammation. Early studies suggest that inhibition of eosinophilic airway inflammation with mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk of exacerbations. We aimed to establish efficacy, safety, and patient characteristics associated with the response to mepolizumab. METHODS: We undertook a multicentre, double-blind, placebo-controlled trial at 81 centres in 13 countries between Nov 9, 2009, and Dec 5, 2011. Eligible patients were aged 12-74 years, had a history of recurrent severe asthma exacerbations, and had signs of eosinophil…

AdultMalemedicine.medical_specialtyAdolescentPlacebo-controlled studyFevipiprantAntibodies Monoclonal HumanizedPlaceboLebrikizumabDrug Administration ScheduleLeukocyte CountYoung Adultchemistry.chemical_compoundDouble-Blind MethodReslizumabInternal medicineSecondary PreventionmedicineHumansAnti-Asthmatic AgentsPulmonary EosinophiliaChildGlucocorticoidsAgedAsthmaDose-Response Relationship Drugbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseBenralizumabAsthmaEosinophilsTreatment OutcomechemistryPhysical therapyDrug Therapy CombinationFemaleInterleukin-5businessMepolizumabmedicine.drugThe Lancet
researchProduct